Historically, SEPT9 was the first septin implicated in cancer 36, and SEPT9 may be a new biomarker of colon cancer, head and neck squamous cell carcinoma, and cervical cancer 37-39. This evidence concerns the gene SEPTIN9 and colonic neoplasm.